These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 17172649)

  • 1. Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease.
    Batzloff MR; Pandey M; Olive C; Good MF
    Immunol Res; 2006; 35(3):233-48. PubMed ID: 17172649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress in M-protein-based subunit vaccines to prevent rheumatic fever and rheumatic heart disease.
    Olive C
    Curr Opin Mol Ther; 2007 Feb; 9(1):25-34. PubMed ID: 17330399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune response against M protein-conserved region peptides from prevalent group A Streptococcus in a North Indian population.
    Gupta VK; Sekhar S; Dhanda V; Toor D; Kumar R; Chakraborti A
    J Microbiol Immunol Infect; 2016 Jun; 49(3):352-8. PubMed ID: 25087198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards a vaccine against rheumatic fever.
    Guilherme L; Faé KC; Higa F; Chaves L; Oshiro SE; Freschi de Barros S; Puschel C; Juliano MA; Tanaka AC; Spina G; Kalil J
    Clin Dev Immunol; 2006; 13(2-4):125-32. PubMed ID: 17162355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rheumatic Heart Disease: Pathogenesis and Vaccine.
    Guilherme L; de Barros SF; Kohler KF; Santos SR; Ferreira FM; Silva WR; Alencar R; Postol E; Kalil J
    Curr Protein Pept Sci; 2018; 19(9):900-908. PubMed ID: 28745221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A vaccine against Streptococcus pyogenes: the potential to prevent rheumatic fever and rheumatic heart disease.
    Guilherme L; Ferreira FM; Köhler KF; Postol E; Kalil J
    Am J Cardiovasc Drugs; 2013 Feb; 13(1):1-4. PubMed ID: 23355360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential for vaccine development against rheumatic fever.
    Medina E; Chhatwal GS
    Indian Heart J; 2002; 54(1):93-8. PubMed ID: 11999099
    [No Abstract]   [Full Text] [Related]  

  • 8. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
    Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
    J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular biology of Group A
    Brahmadathan NK
    Indian J Med Microbiol; 2017; 35(2):176-183. PubMed ID: 28681803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type-specific antibodies to purified streptococcal M proteins from potentially rheumatogenic M-types in patients with rheumatic fever and rheumatic heart disease.
    Thakur A; Singhal S; Prakash K
    J Med Microbiol; 1996 Dec; 45(6):483-9. PubMed ID: 8958254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci.
    Good MF; Pandey M; Batzloff MR; Tyrrell GJ
    Expert Rev Vaccines; 2015; 14(11):1459-70. PubMed ID: 26485214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rheumatic fever: how S. pyogenes-primed peripheral T cells trigger heart valve lesions.
    Guilherme L; Faé KC; Oshiro SE; Tanaka AC; Pomerantzeff PM; Kalil J
    Ann N Y Acad Sci; 2005 Jun; 1051():132-40. PubMed ID: 16126952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody levels to the class I and II epitopes of the M protein and myosin are related to group A streptococcal exposure in endemic populations.
    Brandt ER; Yarwood PJ; McMillan DJ; Vohra H; Currie B; Mammo L; Pruksakorn S; Saour J; Good MF
    Int Immunol; 2001 Oct; 13(10):1335-43. PubMed ID: 11581178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate.
    Batzloff MR; Fane A; Gorton D; Pandey M; Rivera-Hernandez T; Calcutt A; Yeung G; Hartas J; Johnson L; Rush CM; McCarthy J; Ketheesan N; Good MF
    Hum Vaccin Immunother; 2016 Dec; 12(12):3089-3096. PubMed ID: 27541593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of Transthoracic Echocardiography for Cardiac Safety Evaluation in the Clinical Development Process of Vaccines Against Streptococcus pyogenes.
    Nakakana U; Serry-Bangura A; Edem BE; Tessitore P; Di Cesare L; Moriel DG; Podda A; De Ryck IS; Arora AK
    Drugs R D; 2024 Mar; 24(1):1-12. PubMed ID: 38494581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlling acute rheumatic fever and rheumatic heart disease in developing countries: are we getting closer?
    de Dassel JL; Ralph AP; Carapetis JR
    Curr Opin Pediatr; 2015 Feb; 27(1):116-23. PubMed ID: 25490689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of group A streptococcal vaccine development.
    Dale JB
    Adv Exp Med Biol; 2008; 609():53-63. PubMed ID: 18193657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cell response in rheumatic fever: crossreactivity between streptococcal M protein peptides and heart tissue proteins.
    Guilherme L; Faé KC; Oshiro SE; Tanaka AC; Pomerantzeff PM; Kalil J
    Curr Protein Pept Sci; 2007 Feb; 8(1):39-44. PubMed ID: 17305559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine strategies to prevent rheumatic fever.
    Brandt ER; Good MF
    Immunol Res; 1999; 19(1):89-103. PubMed ID: 10374697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeat exposure to group A streptococcal M protein exacerbates cardiac damage in a rat model of rheumatic heart disease.
    Gorton D; Sikder S; Williams NL; Chilton L; Rush CM; Govan BL; Cunningham MW; Ketheesan N
    Autoimmunity; 2016 Dec; 49(8):563-570. PubMed ID: 27562362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.